Cuprior Orphalan · Authorised · authorised 5 Sep 2017 · ATC A16AX
Therapeutic indication (EMA)
Cuprior is indicated for the treatment of Wilson's disease in adults, adolescents and children ≥ 5 years intolerant to D-penicillamine therapy.
Active substance
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Cuprior | 150 mg | Film-coated tablet · Oral use | 72 Blister | SAR 7303.80 | NCE · Prescription | Orphalan | Valid |
WILSON'S DISEASE
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CUVRIOR | 300MG | tablet · oral | ORPHALAN | Prescription | 28 Apr 2022 |
Cuprior is indicated for the treatment of Wilson's disease in adults, adolescents and children ≥ 5 years intolerant to D-penicillamine therapy.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.